SB1317 新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP42651CAS号：1204918-72-8纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	1204918-72-8	货号	BCP42651
关联产品	937270-47-8（SB-1317）
中文名	SB1317
英文名	SB1317
中文别名
英文别名	Ex45; Ex-45; EX 45; TG02; TG 02; TG02; SB1317; SB 1317; Zotiraciclib;
SMILES	CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
化学名称
分子式	C23H24N4O	分子量	372.46
纯度	98%	配送	惯例下常温包邮
产品描述	SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, SB1317 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). SB1317 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias.